DATABASE COMPILATION AND VIRTUAL SCREENING OF SECONDARY METABOLITES DERIVED FROM MARINE FUNGI AS EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE ABSTRACT KINASE INHIBITORS

Authors

  • Mega Watty Department of , Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia.
  • Rezi Riadhi Syahdi Department of , Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia.
  • Arry Yanuar Department of , Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia.

DOI:

https://doi.org/10.22159/ajpcr.2017.v10s5.23118

Keywords:

Marine fungi compounds, Epidermal growth factor receptor-tyrosine kinase, Virtual screening, AutoDock, Vina, Antiproliferative

Abstract

Objective: Epidermal growth factor receptor (EGFR), a transmembrane protein with cytoplasmic kinase activity, transduces growth factor signaling from the extracellular space to the cell. EGFR downstream signaling increases proliferation and reduces apoptosis. Agents that are targeted at intracellular tyrosine kinase are tyrosine kinase inhibitor small molecules, which have a mechanism of action that affects adenosine triphosphate binding to the receptor. The exploration of bioactive compounds from marine materials, including marine fungi, has become a major interest lately for anticancer treatment.

Methods: In this research, a database was created and in silico screening was conducted using AutoDock and Vina to obtain potential marine fungi bioactive compounds as EGFR-tyrosine kinase (EGFR-TK) inhibitors, which act as antiproliferative agents on tumor cell growth.

Results: This research has concluded that the three marine fungi compounds with the lowest binding free energy, FU0015, FU0051, and FU0202, have great potential as inhibitors of EGFR-TK. 

Conclusions: Three active compounds were identified as inhibitors of EGFR-TK, which were Fiscalin A, derived from Neosartorya paulistensis KUFC 7897 (FU0015); Aspergiolide B, derived from Aspergillus flavus (FU0051); and Sporothrix A, derived from Sporothrix sp. (FU0202).

Downloads

Download data is not yet available.

References

da Cunha Santos G, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. Annu Rev Pathol Mech Dis 2011;6(1):49-69.

Mosesson Y, Yarden Y. Oncogenic growth factor receptors: Implications for signal transduction therapy. Semin Cancer Biol 2004;14(4):70-262.

Ciardiello F, Troiani T, Bianco R, Orditura M, Morgillo F, Martinelli E, et al. Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: A rational approach for multi-target anticancer therapy. Ann Oncol 2006;17 Suppl 7:vii109-14.

Choowongkomon K, Sawatdichaikul O, Songtawee N, Limtrakul J. Receptor-based virtual screening of EGFR kinase inhibitors from the NCI diversity database. Molecules 2010;15(6):4041-54.

FDA. FDA Approves Targeted Therapy for First-Line Treatment of Patients with a Type of Metastatic Lung Cancer. FDA News Release; 2015. Available from: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm454678.htm.

Hayashi Y, Yamazaki-Nakamura Y, Yakushiji F. Medicinal chemistry and chemical biology of diketopiperazine-type antimicrotubule and vascular-disrupting agents. Chem Pharm Bull (Tokyo) 2013;61(9):889-901.

Xiong ZQ, Wang JF, Hao YY, Wang Y. Recent advances in the discovery and development of marine microbial natural products. Mar Drugs 2013;11(3):700-17.

Yadav M, Singh G. Bioinformatics: A new era of drug design. Indian J Bioinforma Biotechnol 2013;2(2):48-53.

Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 2009;30(16):2785-91.

Trott O, Olson AJ. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010;31(2):455-61.

Baber JC, Thompson DC, Cross JB, Humblet C. GARD: A generally applicable replacement for RMSD. J Chem Inf Model 2009;49(8):1889-900.

Bender A, Glen RC. A discussion of measures of enrichment in virtual screening: Comparing the information content of descriptors with increasing levels of sophistication. J Chem Inf Model 2005;45(5):1369-75.

Triballeau N, Acher F, Brabet I, Pin JP, Bertrand HO. Virtual screening workflow development guided by the ‘receiver operating characteristic’ curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4. J Med Chem 2005;48(7):2534-47.

Esteves MS. Anticancer Activity of Marine-Derived Fungi Extracts and Isolated Compounds in Human. Abel Salazar Biomedical Science Institute; 2014. Available from: https://www.repositorio-aberto.up.pt/ bitstream/10216/77834/2/33889.pdf.

Gomes NM, Bessa LJ, Buttachon S, Costa PM, Buaruang J, Dethoup T, et al. Antibacterial and antibiofilm activities of tryptoquivalines and meroditerpenes isolated from the marine-derived fungi Neosartorya paulistensis, N. Laciniosa, N. Tsunodae, and the soil fungi N. Fischeri and N. Siamensis. Mar Drugs 2014;12(2):822-39.

Dbm V. In silico screening of secondary metabolites derived from marine fungi for anticancer study. J Adv Bioinform Appl Res 2014;5(2):78-82.

Zhang JY, Tao LY, Liang YJ, Chen LM, Mi YJ, Zheng LS, et al. Anthracenedione derivatives as anticancer agents isolated from secondary metabolites of the mangrove endophytic fungi. Mar Drugs 2010;8(4):1469-81.

Wang X, Mao ZG, Song BB, Chen CH, Xiao WW, Hu B, et al. Advances in the study of the structures and bioactivities of metabolites isolated from mangrove-derived fungi in the South China Sea. Mar Drugs 2013;11(10):3601-16.

Bhatnagar I, Kim SK. Immense essence of excellence: Marine microbial bioactive compounds. Mar Drugs 2010;8(10):2673-701.

Bhimba BV, Franco DA, Jose GM, Mathew JM, Joel EL. Characterization of cytotoxic compound from mangrove derived fungi Irpex hydnoides VB4. Asian Pac J Trop Biomed 2011;1(3):223-6.

Boot CM, Tenney K, Valeriote FA, Crews P. Highly N-methylated linear peptides produced by an atypical sponge-derived Acremonium sp. J Nat Prod 2006;69(1):83-92.

Cao F, Yang Q, Shao CL, Kong CJ, Zheng JJ, Liu YF, et al. Bioactive 7-oxabicyclic[6.3.0]lactam and 12-membered macrolides from a gorgonian-derived Cladosporium sp. Fungus. Mar Drugs 2015;13(7):4171-8.

Debbab A, Aly AH, Proksch P. Endophytes and associated marine derived fungi-ecological and chemical perspectives. Fungal Divers 2012;57(1):1-39.

Debbab A, Aly AH, Lin WH, Proksch P. Bioactive compounds from marine bacteria and fungi. Microb Biotechnol 2010;3(5):544-63.

Gomes N, Lefranc F, Kijjoa A, Kiss R. Can some marine-derived fungal metabolites become actual anticancer agents? Mar Drugs 2015;13(6):3950-91.

Tarman K, Palm GJ, Porzel A, Merzweiler K, Arnold N, Wessjohann LA, et al. A new lactone from an Indonesian marine algicolous strain of Daldinia eschscholzii (Xylariaceae, Ascomycota). Phytochem Lett 2012;5(1):83-6.

Li YX, Himaya SW, Dewapriya P, Zhang C, Kim SK. Fumigaclavine C from a marine-derived fungus Aspergillus fumigatus induces apoptosis in MCF-7 breast cancer cells. Mar Drugs 2013;11(12):5063-86.

Prompanya C, Fernandes C, Cravo S, Pinto M, Silva A, Kijjoa A, et al. A new cyclic hexapeptide and a new isocoumarin derivative from the marine sponge-associated fungus Aspergillus similanensis KUFA 0013. Mar Drugs 2015;13(3):1432-50.

Vasanthabharathi V, Jayalakshmi S. Review on bioactive potential of marine microbes. Afr J Microbiol Res 2013;7(39):4683-8.

Tao LY, Zhang JY, Liang YJ, Chen LM, Zhen LS, Wang F, et al. Anticancer effect and structure-activity analysis of marine products isolated from metabolites of mangrove fungi in the South China Sea. Mar Drugs 2010;8(4):1094-105.

Tohme R, Darwiche N, Gali-Muhtasib H. A journey under the sea: The quest for marine anti-cancer alkaloids. Molecules 2011;16(11):9665-96.

Kim SK. Marine Microbiology: Bioactive Compounds and Biotechnological Applications. Germany: John Wiley & Sons; 2013.

Swathi J. Marine fungal metabolites as a rich source of bioactive compounds. Afr J Biochem Res 2013;7(10):184-96.

Yosaatmadja JU, Squire Y, McKeage CJ, Flanagan M. 1.85 angstrom structure of EGFR kinase domain with gefitinib. To Be Publ; 2014.

Published

01-10-2017

How to Cite

Watty, M., R. R. Syahdi, and A. Yanuar. “DATABASE COMPILATION AND VIRTUAL SCREENING OF SECONDARY METABOLITES DERIVED FROM MARINE FUNGI AS EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE ABSTRACT KINASE INHIBITORS”. Asian Journal of Pharmaceutical and Clinical Research, vol. 10, no. 17, Oct. 2017, pp. 142-7, doi:10.22159/ajpcr.2017.v10s5.23118.

Issue

Section

Original Article(s)

Most read articles by the same author(s)